基于伊梅格林的疗法改善了血糖控制,减少了2型糖尿病中的线粒体压力:一项前性队列研究
Abhishek Satheesan1, Janardanan Subramonia Kumar2, Leela Kakithakara Vajravelu1
1Department of Microbiology, SRM Medical College Hospital and Research Centre, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, Tamil Nadu, India.
Frontiers in endocrinology
|October 9, 2025
概括
与其他口服药物相结合的伊梅格林明显地改善了血糖控制,并减少了2型糖尿病患者的炎症和线粒体应激. 这表明imeglimin作为一种附加疗法提供了更广泛的代谢益处.
科学领域:
- 内分泌学和新陈代谢学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 伊梅格林是一种新的口服抗糖尿病药物,具有已知的线粒体和抗炎性质.
- 2型糖尿病 (T2DM) 的特点是高血糖,线粒体功能障碍和慢性炎症.
- 评估伊梅格林对血糖控制,线粒体压力标志物和T2DM炎症标志物的影响至关重要.
研究的目的:
- 评估基于伊梅格林的疗法在改善T2DM患者的血糖控制方面的疗效.
- 评估伊梅格林对线粒体压力的影响,通过循环无细胞线粒体DNA (ccf-mtDNA) 来测量.
- 确定伊梅格林对关键炎症标志物的影响,包括NLRP3,IL-6,IL-1β和IL-18.
主要方法:
- 一项临床试验涉及104名T2DM患者,随机分为四组:伊梅格林单一治疗,伊梅格林+甲福林,伊梅格林+其他口服低血糖剂 (OHAs),以及甲福林+其他OHAs.
- 关键的代谢和炎症生物标志物 (HbA1c,脂质谱,ccf-mtDNA,NLRP3,IL-6,IL-1β,IL-18) 在基线和6个月后被评估.
- 统计分析包括配对t测试,反复测量ANCOVA和相关性分析,以评估治疗效果和关联.
主要成果:
- 基于伊梅格林的组合疗法,特别是与非甲胺OHA的组合疗法,显著降低了HbA1c,ccf-mtDNA和IL-6水平.
- 在imeglimin治疗组中,ANCOVA显示了HbA1c,ccf-mtDNA和NLRP3的显著降低.
- 在伊梅格林林+其他OHA组中观察到显著改善,IL-6和IL-1β显著减少,但IL-18没有变化.
结论:
- 伊梅格林,特别是与非甲胺OHA结合时,有效地改善T2DM中的血糖控制.
- 伊梅格林林治疗减少了线粒体压力和炎症的标志物,这表明更广泛的代谢益处.
- 这些发现支持使用伊梅格林作为T2DM管理的辅助疗法.
相关概念视频
Diabetes: Management and Pharmacotherapy
867
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
867
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones
583
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
583
Dipeptidyl Peptidase 4 Inhibitors
587
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
587
Diabetes Mellitus: Overview and Type I Subtype
4.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.9K
Glucagon-like Receptor Agonists
841
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
841


